Bionano Genomics (BNGO) Net Equity Issued and Repurchased (2019 - 2026)

Bionano Genomics (BNGO) has 8 years of Net Equity Issued and Repurchased data on file, last reported at $705000.0 in Q1 2026.

• For the quarter ending Q1 2026, Net Equity Issued and Repurchased fell 94.71% year-over-year to $705000.0; the trailing twelve-month figure through Mar 2026 stood at $18.5 million (down 56.3% YoY), and the FY2025 full-year result was $31.1 million, down 30.01% from the prior year.
• Net Equity Issued and Repurchased declined to $705000.0 in Q1 2026, from $1.8 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $23.1 million in Q3 2022 to a low of $705000.0 in Q1 2026.
• A 5-year average of $11.2 million and a median of $12.5 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased surged 64.3% in 2022 and sank 94.71% in 2026, its largest moves.
• Tracing BNGO's Net Equity Issued and Repurchased over 5 years: stood at $23.1 million in 2022, then plunged by 51.2% to $11.3 million in 2023, then slumped by 40.45% to $6.7 million in 2024, then sank by 73.95% to $1.8 million in 2025, then sank by 59.74% to $705000.0 in 2026.
• Business Quant data shows BNGO's Net Equity Issued and Repurchased at $705000.0 in Q1 2026, $1.8 million in Q4 2025, and $12.9 million in Q3 2025.